IP Library Granted Patent US 9,688,991
Granted Patent B2
US 9,688,991 · App. 14/413,727 · Granted Jun 27, 2017

Aptamer-targetted antigen delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,688,991
App. No.
14/413,727
Granted
Jun 27, 2017
Kind
B2
Abstract

A composition is provided comprising an oligonucleotide aptamer conjugated to an antigen, wherein the aptamer is directed against a cell-surface target of an antigen-presenting cell. Also provided are methods of delivering an antigen to a dendritic cell and of eliciting an immune response in a subject.

Claims (13)

1. A composition comprising an oligonucleotide aptamer comprising the sequence set forth in SEQ ID NO:1 conjugated to an antigen.

2. The composition of claim 1 , wherein the aptamer comprises an oligoribonucleotide.

3. The composition of claim 1 , wherein the aptamer is PEGylated.

4. The composition of claim 1 , wherein the aptamer consists of the sequence set forth in SEQ ID NO:1.

5. The composition of claim 1 , wherein the aptamer further comprises a 3′ inverted dT.

6. The composition of claim 1 , further comprising one or more additional oligonucleotide aptamers conjugated to the antigen, wherein the aptamers are directed against a cell-surface target of an antigen-presenting cell.

7. The composition of claim 1 , wherein the antigen is a vaccine molecule.

8. The composition of claim 1 , wherein the composition further comprises an immunological adjuvant.

9. A method of presenting an antigen to a dendritic cell, comprising contacting the dendritic cell with the composition of claim 1 comprising the antigen.

10. A method of eliciting an immune response in a subject comprising administering to the subject the composition of claim 1 comprising the antigen, in an amount effective to elicit an immune response.

11. The method of claim 10 , wherein the antigen-presenting cell is a dendritic cell.

12. The method of claim 10 , wherein the antigen is a vaccine molecule.

13. The method of claim 10 , wherein the cell-surface target is a DEC-205 receptor molecule.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded Feb 26, 2019
From: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.; ALBERT EINSTEIN COLLEGE OF MEDICINE
To: ALBERT EINSTEIN COLLEGE OF MEDICINE
Reel/Frame 048438/0275 →
CHANGE OF NAME Recorded Oct 20, 2015
From: COM AFFILIATION, INC.
To: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Reel/Frame 036907/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
To: COM AFFILIATION, INC.
Reel/Frame 036876/0363 →